Harshalata Kanwar

This study discusses the complex mechanisms through which enzymes catalyze biochemical reactions, highlighting their efficiency, specificity, and structural flexibility. Acid-base catalysis, covalent catalysis, metal ion catalysis, and transition state stabilization are some of the distinct yet combined catalytic techniques that enzymes use to lower activation energy and speed up reactions. Our understanding of enzyme-substrate interactions, conformational change, and reaction kinetics has significantly increased thanks to advancements in structural biology techniques including X-ray crystallography, cryo-electron microscopy (cryo-EM), and molecular dynamics simulations. The understanding developed through enzymology has deep-rooted impacts across a range of disciplines, from drug development where enzyme inhibitors are key to the treatment of diseases like HIV and hypertension to biotechnology, where designed enzymes are transforming industrial catalysis, biofuel manufacture, and bioremediation. Furthermore, the coupling of artificial intelligence (AI) and machine learning is opening up possibilities for predictive modeling and the development of new biocatalysts with designed functions. Although enzyme research has come a long way, it is still challenging to capture transient catalytic states, elucidate enzyme behavior in cellular environments, and maximize enzyme efficiency for synthetic purposes. With continued advances in research, enzymes will continue to be at the center of scientific and technological innovations, leading the way in medicine, industry, and green chemistry.

Nanoparticle-mediated drug delivery systems have revolutionized the science of pharmaceutics by overcoming pivotal issues related to traditional drug administration, including solubility limitations, fast degradation, and systemic toxicity. Such systems employ several nanoscale carriers, like liposomes, polymeric nanoparticles, dendrimers, and solid lipid nanoparticles, each for increasing drug stability, bioavailability, and target-oriented delivery to the desired tissue or cellular receptors. The inclusion of surface modifications, for example, ligand functionalization and PEGylation, have greatly enhanced nanoparticle circulation time, decreased immune clearance, and enabled targeted delivery of drugs with high accuracy, thus improving therapeutic efficacy while lowering toxicity. In addition, novel developments in hybrid nanoparticle platforms that combine organic and inorganic components have enhanced the functionality of drug carriers, enabling improved tunability in drug release kinetics. Besides that, the establishment of stimuli-sensitive nanoparticles that respond to physiological signals like pH, temperature, or enzymatic actions has made high-level and target-specific drug delivery possible, still enhancing therapeutic impacts. In contrast to these prospects, however, issues like scaling up production for large quantities, high cost, regulatory challenges, and long-term toxicity are outstanding impediments against extensive clinical up-take. Overcoming these limitations by sustained research in the fields of nanotechnology, materials science, and biomedical engineering is imperative for the optimal use of nanoparticle-based drug delivery platforms. With progressive development, such systems are well-positioned to become a revolutionizing force behind precision medicine, especially in cancer treatment, neurodegenerative disorders, and infectious diseases, paving the way to more efficacious and patient-specific therapeutic regimens

Cancer is a major global cause of death that requires new approaches to treatment outside the use of traditional chemotherapy, radiotherapy, and surgery. Nanomedicine, based on the application of nanoparticles (NPs) to targeted drug delivery, offers an exciting area of research for increased therapeutic benefits while reducing side effects. In this review, developments in nanotechnology-based drug delivery systems (DDSs) are discussed, focusing on their value in transcending multidrug resistance (MDR), improving bioavailability, and increasing the specificity of treatment. Several NP-based systems, such as liposomes, polymeric NPs, metal NPs, and quantum dots, are analyzed with respect to cancer therapy. Additionally, this paper addresses issues with clinical translation, including biocompatibility, toxicity, and regulatory issues. At last, upcoming trends and directions of future studies to optimize NP-based cancer treatments are presented.

Synthetic as well as cell-based nanocarriers have come into great consideration for treating neurodegenerative diseases as well as other cerebral conditions. How well the brain-targeting delivery of drugs happens using Nano formulations is hugely determined by the physicochemical parameters such as size, shape, hydrophobicity, elasticity, and charge/chemistry/morphology at the surface of the drug nanocarrier, which determines their mode of interaction with living systems. One of the key determinants of their in vivo behavior is the protein corona formation, which governs nanoparticle recognition, circulation, and biodistribution. It is important to understand the biological matrices and cell culture compositions involved in protein corona formation in order to design efficient nanomedicines. In addition, characterization of nanocarriers in complex biological environments poses specific challenges, and advanced analytical methods need to be developed and used. This review discusses the types and properties of brain-targeted nanocarriers, there in vivo interactions, and the characterization methods employed for them. We also discuss the strengths and weaknesses of existing analytical tools, the difficulties in applying these methods in a Good Manufacturing Practice (GMP) setting, and the promise of orthogonal complementary characterization methods. By overcoming these challenges, this review will offer the insights into how the translational value of nanomedicines in brain disorders can be improved.

Nanoparticle drug delivery systems have evolved as a revolutionary approach to the treatment of cardiovascular diseases (CVDs). These systems present a highly hopeful alternative to traditional drugs, which often have limited bioavailability, systemic toxicity, poor solubility, and a dearth of targeted therapeutic effect. Liposomal, polymeric, metallic, and dendrimer-based nanoparticles are just a few examples of nanoscale carriers that can deliver drugs to injured tissues in a targeted fashion. This facilitates controlled and sustained drug release while at the same time reducing off-targeting effects. Nanotechnology can potentially enhance therapeutic responses significantly by aiding in the stabilization of medication, circulation time, and cellular internalization. This, in turn, will help to reduce unwanted effects and enhance patient care. The application of nanoparticles in tissue engineering is not only limited to the delivery of drugs but also plays a critical role in the regeneration of heart tissue and function as good contrast agents for imaging purposes, allowing for real-time monitoring of diseases. However, despite their enormous promise, their widespread clinical use is hampered by obstacles such as the toxicity of nanoparticles, the quick clearance of the immune system, intricacy of manufacture on a large scale, and onerous regulatory approval procedures. The effective integration of nanoparticle therapeutics with traditional cardiovascular treatment will depend upon the successful solution of these issues through the creation of biocompatible materials, effective surface modifications, and scalable manufacturing processes. Under the purview of this research, the latest advances in drug delivery through nanotechnology are explored, the mechanisms by which therapeutic action is enhanced are explored, and the potential future directions for implementing these advances into cardiovascular therapy protocols are explored.

This study explores transdermal insulin patch technology as a possible alternative to conventional subcutaneous insulin injections in managing diabetes mellitus. A quasi-experimental design was utilized in this study, comparing the efficacy, safety, patient satisfaction, and adherence of insulin patches with subcutaneous insulin injections. A total of 150 adults, 75 in each group, with a medical diagnosis of either Type 1 or Type 2 diabetes mellitus, were recruited from diabetes management clinics. Glycemic parameters were measured pre- and post-intervention for six months on both groups, including HbA1c and glucose levels while fasting. Results indicated that both the treatment groups revealed significant reductions in HbA1c and fasting glucose. The insulin patch group had an even more pronounced reduction in HbA1c and glucose levels. The insulin patch was well-tolerated, with only 12% of participants experiencing mild skin irritation. Patient satisfaction was significantly higher in the experimental group, with 88% rating the insulin patch as "very convenient" compared to 46% in the control group.